Your browser is no longer supported. Please, upgrade your browser.
Settings
ONTX Onconova Therapeutics, Inc. daily Stock Chart
ONTX [NASD]
Onconova Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.52 Insider Own0.20% Shs Outstand168.67M Perf Week-2.07%
Market Cap94.41M Forward P/E- EPS next Y-0.14 Insider Trans28.01% Shs Float166.98M Perf Month18.95%
Income-19.00M PEG- EPS next Q-0.03 Inst Own7.80% Short Float5.13% Perf Quarter80.73%
Sales2.20M P/S42.92 EPS this Y70.00% Inst Trans- Short Ratio0.82 Perf Half Y23.88%
Book/sh0.13 P/B4.37 EPS next Y-16.70% ROA-108.00% Target Price- Perf Year-78.34%
Cash/sh0.19 P/C3.05 EPS next 5Y- ROE-340.20% 52W Range0.10 - 2.85 Perf YTD48.17%
Dividend- P/FCF- EPS past 5Y67.90% ROI-187.10% 52W High-80.06% Beta2.19
Dividend %- Quick Ratio4.60 Sales past 5Y22.20% Gross Margin- 52W Low452.58% ATR0.05
Employees25 Current Ratio4.60 Sales Q/Q0.00% Oper. Margin- RSI (14)55.16 Volatility5.55% 10.86%
OptionableNo Debt/Eq0.00 EPS Q/Q97.50% Profit Margin- Rel Volume0.31 Prev Close0.56
ShortableYes LT Debt/Eq0.00 EarningsMay 14 AMC Payout- Avg Volume10.49M Price0.57
Recom2.00 SMA20-2.23% SMA5021.66% SMA20023.16% Volume3,200,546 Change1.34%
Mar-01-18Reiterated H.C. Wainwright Buy $6 → $7.50
Jan-17-18Downgrade Maxim Group Buy → Hold
Oct-09-17Initiated H.C. Wainwright Buy $6
Apr-27-17Initiated Laidlaw Buy $10
Jul-01-15Upgrade Piper Jaffray Neutral → Overweight
May-05-15Initiated H.C. Wainwright Buy $6
Jul-07-20 08:00AM  
Jun-23-20 10:43AM  
08:00AM  
Jun-22-20 08:00AM  
Jun-12-20 08:00AM  
Jun-08-20 08:00AM  
May-28-20 09:44AM  
May-18-20 11:33AM  
May-14-20 04:05PM  
May-11-20 08:00AM  
May-07-20 08:00AM  
Apr-27-20 08:00AM  
Apr-07-20 06:40AM  
Apr-02-20 07:00AM  
Mar-24-20 04:05PM  
Mar-18-20 08:00AM  
Mar-13-20 09:46AM  
Mar-02-20 09:54AM  
Feb-21-20 10:12AM  
Feb-20-20 08:45AM  
07:03AM  
Feb-19-20 11:19AM  
Feb-18-20 10:06AM  
08:00AM  
Feb-10-20 08:00AM  
Feb-04-20 08:00AM  
Jan-23-20 05:44PM  
08:30AM  
Jan-03-20 01:27PM  
Jan-02-20 01:48PM  
Dec-31-19 11:30AM  
Dec-23-19 07:33PM  
Dec-19-19 01:44PM  
Dec-18-19 09:05AM  
09:00AM  
Dec-17-19 07:30AM  
Dec-10-19 03:07PM  
Dec-09-19 09:00AM  
08:00AM  
Dec-07-19 08:35AM  
Dec-06-19 08:49AM  
07:30AM  
Nov-25-19 09:26AM  
Nov-22-19 02:46PM  
Nov-21-19 11:23AM  
10:16AM  
Nov-07-19 07:30AM  
Oct-24-19 07:30AM  
Sep-24-19 10:15AM  
Sep-23-19 08:52AM  
Sep-19-19 07:39AM  
Sep-18-19 10:05AM  
Sep-16-19 07:30AM  
Aug-23-19 01:23PM  
Aug-14-19 07:30AM  
Aug-12-19 07:30AM  
Aug-07-19 07:30AM  
Aug-06-19 10:30AM  
Jun-10-19 07:30AM  
May-30-19 06:26PM  
May-28-19 07:30AM  
May-14-19 07:30AM  
May-13-19 12:52PM  
07:30AM  
May-07-19 07:30AM  
May-06-19 07:30AM  
Apr-02-19 07:30AM  
02:36AM  
Mar-26-19 07:30AM  
Mar-25-19 07:30AM  
Mar-19-19 07:30AM  
Mar-12-19 07:30AM  
Feb-04-19 08:00AM  
Jan-31-19 07:30AM  
Jan-22-19 07:30AM  
Jan-16-19 01:08PM  
Jan-15-19 05:15PM  
Jan-02-19 07:30AM  
Dec-31-18 07:30AM  
Dec-10-18 07:30AM  
Dec-03-18 07:30AM  
Nov-16-18 01:47PM  
Nov-13-18 07:00AM  
Nov-07-18 08:30AM  
Nov-06-18 10:30AM  
Nov-05-18 08:30AM  
Nov-01-18 08:30AM  
Oct-29-18 08:30AM  
Oct-17-18 08:30AM  
Oct-10-18 08:30AM  
Sep-27-18 08:00AM  
Sep-26-18 12:12PM  
Sep-25-18 09:16AM  
Aug-21-18 09:46AM  
08:30AM  
Aug-14-18 08:00AM  
07:00AM  
Aug-07-18 08:00AM  
Jul-17-18 07:25AM  
Jun-21-18 08:00AM  
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. The company has a license agreement with SymBio Pharmaceuticals Limited; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of ON 123300 in Greater China. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GROOPMAN JEROMEDirectorMay 19Buy0.3610,0003,62610,001May 21 05:10 PM
OLER ABRAHAM N.SVP Corp Dev & Gen CounselMay 19Buy0.3715,0005,55090,000May 20 09:19 AM
Guerin Mark PatrickChief Financial OfficerMay 19Buy0.3621,0007,560108,844May 20 09:09 AM
Fruchtman Steven MPresident, Chief Executive OffMay 19Buy0.3726,8009,857176,226May 20 09:07 AM
Reddy E PremkumarDirectorNov 25Buy0.20500,000100,000544,546Nov 26 07:57 AM
MARINO JAMES JDirectorNov 25Buy0.20150,00030,000166,942Nov 26 07:53 AM
Fruchtman Steven MPresident, Chief Executive OffNov 25Buy0.20149,00029,800149,426Nov 26 07:51 AM
Guerin Mark PatrickChief Financial OfficerNov 25Buy0.2087,50017,50087,844Nov 26 07:50 AM
OLER ABRAHAM N.VP Corp Dev & Gen CounselNov 25Buy0.2075,00015,00075,000Nov 26 07:46 AM
MEHTA VIRENDirectorNov 25Buy0.20250,00050,000250,857Nov 27 08:33 AM
MARINO JAMES JDirectorSep 25Buy1.607,26011,61616,942Sep 26 06:22 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerSep 24Sale1.1916,70019,873616,389Sep 26 04:16 PM
ARMISTICE CAPITAL, LLC10% OwnerSep 23Sale1.2710,24913,016816,702Sep 25 05:41 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerSep 23Sale1.2337,24245,968633,089Sep 24 04:08 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerSep 20Sale1.6275,119121,430670,331Sep 24 04:08 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerSep 18Sale2.1049,995105,014745,450Sep 20 04:05 PM
683 Capital Management, LLCFormer 10% OwnerSep 18Sale2.03506,8771,030,684460,000Sep 20 03:21 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerSep 11Sale2.751,2473,432795,445Sep 13 04:24 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerSep 09Sale2.774001,106796,692Sep 11 04:16 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerSep 06Sale2.785,01513,954797,092Sep 09 04:10 PM
TYNDALL CAPITAL PARTNERS L P10% OwnerSep 05Sale2.754001,100802,107Sep 09 04:10 PM